PJP — Invesco Pharmaceuticals ETF
Data updated: 2026-07-13
PJP — Invesco Pharmaceuticals ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $333.09M AUM · 0.57% expense ratio · 29.5% 1-yr return. From SEC regulatory filings.
PJP Fund Overview
PJP — Invesco Pharmaceuticals ETF is a US ETF managed by Invesco Exchange-Traded Fund Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Invesco Exchange-Traded Fund Trust
- Category: United States Health Care Equity
- Assets under management: $333.09M
- 1-year return: 29.5%
- Ticker: PJP
- SEC CIK: 0001209466
- SEC series ID: S000003031
- Share class ID: C000008298
PJP Holdings
Top 10 holdings of Invesco Pharmaceuticals ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Invesco Private Prime Fund | 12.06% |
| Pfizer Inc. | 5.21% |
| Johnson & Johnson | 4.95% |
| AbbVie Inc. | 4.90% |
| Amgen Inc. | 4.79% |
| Eli Lilly and Co. | 4.76% |
| Gilead Sciences, Inc. | 4.70% |
| Merck & Co., Inc. | 4.67% |
| Invesco Private Government Fund | 4.64% |
| Abbott Laboratories | 4.20% |
PJP Portfolio Allocation
Asset-class allocation of Invesco Pharmaceuticals ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 100.3% |
| Cash & Equivalents | 16.8% |
PJP Performance
Total returns for PJP (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 0.8% |
| 1 year | 29.5% |
| 3 years (annualised) | 11.8% |
| 5 years (annualised) | 7.2% |
PJP Risk Information
Risk metrics for PJP, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.5%
PJP Costs and Fees
PJP costs about $57 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.57%
- Gross expense ratio: 0.57%
- Portfolio turnover: 48%
- Brokerage commissions: 2.81 bps of average net assets (SEC N-CEN)
PJP Cashflows
Over the 12 months to 2026-04, Invesco Pharmaceuticals ETF had net inflows of $23.84M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | −$70.57M |
| 2026-03 | −$2.02M |
| 2026-02 | $4.49M |
| 2026-01 | $85.56M |
| 2025-12 | $7.40M |
| 2025-11 | $8.03M |
PJP Debt Constituents
No individual debt constituents are reported in Invesco Pharmaceuticals ETF's latest SEC N-PORT filing.
PJP Prospectus and SEC Filings
Official Invesco Pharmaceuticals ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.